Monoclonals against malaria: the promise of passive protection

In The Lancet Infectious Diseases, Kirsten Lyke and colleagues 1 Lyke KE Berry AA Mason K et al. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. Lancet Infect Dis. 2023; (published online Jan 25.)https://doi.org/10.1016/S1473-3099(22)00793-9 Google Scholar report the findings of the third part of a three-part trial evaluating low doses of the monoclonal antibody CIS43LS, administered intravenously or subcutaneously, for protection against Plasmodium falciparum in controlled human malaria infection. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialCIS43LS was safe and well tolerated, and conferred protection against P falciparum at low doses and by the subcutaneous route, providing evidence that this approach might be useful to prevent malaria across several clinical use cases. Full-Text PDF